# Kwok Kin Wong

## List of Publications by Citations



| | | | |
|---|---|---|---|
| 290 papers | 39,617 citations | 104 h-index | 195 g-index |
| 325 ext. papers | 47,177 ext. citations | 16.3 avg, IF | 6.77 L-index |

| # | Paper | IF | Citations |
|---|---|---|---|
| 290 | A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. *Cell*, **2010**, 141, 69-80 | 56.2 | 1638 |
| 289 | The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. *Proceedings of the National Academy of Sciences of the United States of America*, **2008**, 105, 2070-5 | 11.5 | 1431 |
| 288 | Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. *Nature Medicine*, **2008**, 14, 1351-6 | 50.5 | 1121 |
| 287 | Non-small-cell lung cancers: a heterogeneous set of diseases. *Nature Reviews Cancer*, **2014**, 14, 535-46 | 31.3 | 934 |
| 286 | The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. *Science*, **2014**, 343, 305-9 | 33.3 | 876 |
| 285 | High-throughput oncogene mutation profiling in human cancer. *Nature Genetics*, **2007**, 39, 347-51 | 36.3 | 847 |
| 284 | Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. *Nature Communications*, **2016**, 7, 10501 | 17.4 | 846 |
| 283 | Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. *Cancer Discovery*, **2013**, 3, 1355-63 | 24.4 | 831 |
| 282 | A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. *Cell*, **2009**, 137, 835-48 | 56.2 | 784 |
| 281 | LKB1 modulates lung cancer differentiation and metastasis. *Nature*, **2007**, 448, 807-10 | 50.4 | 774 |
| 280 | Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. *Nature*, **2009**, 462, 1070-4 | 50.4 | 766 |
| 279 | SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. *Nature Genetics*, **2009**, 41, 1238-42 | 36.3 | 733 |
| 278 | Mutations and PD-1 Inhibitor Resistance in -Mutant Lung Adenocarcinoma. *Cancer Discovery*, **2018**, 8, 822-835 | 24.4 | 648 |
| 277 | PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. *Cancer Research*, **2007**, 67, 11924-32 | 10.1 | 589 |
| 276 | EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. *Cancer Cell*, **2013**, 23, 677-92 | 24.3 | 547 |
| 275 | Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities. *Cancer Discovery*, **2015**, 5, 860-77 | 24.4 | 476 |
| 274 | A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. *Cancer Research*, **2011**, 71, 6051-60 | 10.1 | 468 |

| | | | |
|---|---|---|---|
| 273 | Neutrophil elastase-mediated degradation of IRS-1 accelerates lung tumor growth. *Nature Medicine* , **2010**, 16, 219-23 | 50.5 | 465 |
| 272 | Targeting the PI3K signaling pathway in cancer. *Current Opinion in Genetics and Development*, **2010**, 20, 87-90 | 4.9 | 441 |
| 271 | Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors. *Nature*, **2016**, 534, 129-32 | 50.4 | 414 |
| 270 | Telomere shortening and mood disorders: preliminary support for a chronic stress model of accelerated aging. *Biological Psychiatry*, **2006**, 60, 432-5 | 7.9 | 391 |
| 269 | Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. *Cancer Discovery*, **2011**, 1, 78-89 | 24.4 | 389 |
| 268 | The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. *Cancer Cell*, **2006**, 9, 485-95 | 24.3 | 389 |
| 267 | CDK7 inhibition suppresses super-enhancer-linked oncogenic transcription in MYCN-driven cancer. *Cell*, **2014**, 159, 1126-1139 | 56.2 | 386 |
| 266 | A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response. *Nature*, **2012**, 483, 613-7 | 50.4 | 361 |
| 265 | Repression of c-myc transcription by Blimp-1, an inducer of terminal B cell differentiation. *Science*, **1997**, 276, 596-9 | 33.3 | 353 |
| 264 | Telomere dysfunction and Atm deficiency compromises organ homeostasis and accelerates ageing. *Nature*, **2003**, 421, 643-8 | 50.4 | 330 |
| 263 | Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers. *Nature*, **2007**, 447, 966-71 | 50.4 | 327 |
| 262 | High-resolution genomic profiles of human lung cancer. *Proceedings of the National Academy of Sciences of the United States of America*, **2005**, 102, 9625-30 | 11.5 | 326 |
| 261 | CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation. *Cancer Discovery*, **2018**, 8, 216-233 | 24.4 | 308 |
| 260 | STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment. *Cancer Research*, **2016**, 76, 999-1008 | 10.1 | 297 |
| 259 | The dTAG system for immediate and target-specific protein degradation. *Nature Chemical Biology*, **2018**, 14, 431-441 | 11.7 | 295 |
| 258 | Targeting transcriptional addictions in small cell lung cancer with a covalent CDK7 inhibitor. *Cancer Cell*, **2014**, 26, 909-922 | 24.3 | 294 |
| 257 | Drug-sensitive FGFR2 mutations in endometrial carcinoma. *Proceedings of the National Academy of Sciences of the United States of America*, **2008**, 105, 8713-7 | 11.5 | 292 |
| 256 | Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. *Immunity*, **2017**, 46, 197-204 | 32.3 | 288 |

| | | | |
|---|---|---|---|
| 255 | Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer. *Nature*, **2014**, 513, 110-4 | 50.4 | 288 |
| 254 | Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models. *Cancer Cell*, **2013**, 23, 121-8 | 24.3 | 288 |
| 253 | Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing. *Nature Medicine*, **2006**, 12, 852-5 | 50.5 | 283 |
| 252 | mRNA circularization by METTL3-eIF3h enhances translation and promotes oncogenesis. *Nature*, **2018**, 561, 556-560 | 50.4 | 283 |
| 251 | GOLPH3 modulates mTOR signalling and rapamycin sensitivity in cancer. *Nature*, **2009**, 459, 1085-90 | 50.4 | 276 |
| 250 | Loss of Lkb1 and Pten leads to lung squamous cell carcinoma with elevated PD-L1 expression. *Cancer Cell*, **2014**, 25, 590-604 | 24.3 | 273 |
| 249 | Telomere dysfunction impairs DNA repair and enhances sensitivity to ionizing radiation. *Nature Genetics*, **2000**, 26, 85-8 | 36.3 | 267 |
| 248 | Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition. *Proceedings of the National Academy of Sciences of the United States of America*, **2009**, 106, 19503-8 | 11.5 | 262 |
| 247 | Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors. *Nature Genetics*, **2018**, 50, 1271-1281 | 36.3 | 249 |
| 246 | Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors. *Cancer Cell*, **2016**, 29, 255-269 | 24.3 | 244 |
| 245 | Transcription factor NRF2 regulates miR-1 and miR-206 to drive tumorigenesis. *Journal of Clinical Investigation*, **2013**, 123, 2921-34 | 15.9 | 232 |
| 244 | An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor. *Cancer Research*, **2005**, 65, 7096-101 | 10.1 | 231 |
| 243 | Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors. *Proceedings of the National Academy of Sciences of the United States of America*, **2006**, 103, 7817-22 | 11.5 | 229 |
| 242 | Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids. *Cancer Discovery*, **2018**, 8, 196-215 | 24.4 | 228 |
| 241 | An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation. *Cancer Research*, **2010**, 70, 2485-94 | 10.1 | 227 |
| 240 | Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer. *Proceedings of the National Academy of Sciences of the United States of America*, **2009**, 106, 18351-6 | 11.5 | 226 |
| 239 | Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer. *Nature Medicine*, **2018**, 24, 638-646 | 50.5 | 213 |
| 238 | Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors. *Cancer Discovery*, **2012**, 2, 934-47 | 24.4 | 212 |

| | | | |
|---|---|---|---|
| 237 | False-Positive Plasma Genotyping Due to Clonal Hematopoiesis. *Clinical Cancer Research*, **2018**, 24, 4437-4443 | 10.2 | 210 |
| 236 | Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2. *Proceedings of the National Academy of Sciences of the United States of America*, **2012**, 109, 14476-81 | 11.5 | 208 |
| 235 | A genetic screen identifies an LKB1-MARK signalling axis controlling the Hippo-YAP pathway. *Nature Cell Biology*, **2014**, 16, 108-17 | 23.4 | 205 |
| 234 | Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions. *Journal of Clinical Investigation*, **2009**, 119, 1727-40 | 15.9 | 205 |
| 233 | Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition. *Nature Medicine*, **2011**, 17, 875-82 | 50.5 | 204 |
| 232 | Exploiting cancer cell vulnerabilities to develop a combination therapy for ras-driven tumors. *Cancer Cell*, **2011**, 20, 400-13 | 24.3 | 199 |
| 231 | Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy. *Journal of the National Cancer Institute*, **2012**, 104, 476-87 | 9.7 | 196 |
| 230 | Somatic LKB1 mutations promote cervical cancer progression. *PLoS ONE*, **2009**, 4, e5137 | 3.7 | 195 |
| 229 | Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy. *Cancer Cell*, **2007**, 12, 81-93 | 24.3 | 193 |
| 228 | A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer. *Clinical Cancer Research*, **2013**, 19, 3068-77 | 12.9 | 192 |
| 227 | Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer. *Nature Medicine*, **2014** , 20, 1027-34 | 50.5 | 191 |
| 226 | Rescue of Hippo coactivator YAP1 triggers DNA damage-induced apoptosis in hematological cancers. *Nature Medicine*, **2014**, 20, 599-606 | 50.5 | 189 |
| 225 | Evidence for an alternative fatty acid desaturation pathway increasing cancer plasticity. *Nature*, **2019**, 566, 403-406 | 50.4 | 187 |
| 224 | Integrative genomic and proteomic analyses identify targets for Lkb1-deficient metastatic lung tumors. *Cancer Cell*, **2010**, 17, 547-59 | 24.3 | 187 |
| 223 | LKB1 loss links serine metabolism to DNA methylation and tumorigenesis. *Nature*, **2016**, 539, 390-395 | 50.4 | 173 |
| 222 | Prostate cancer-associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4. *Nature Medicine*, **2017**, 23, 1063-1071 | 50.5 | 169 |
| 221 | Autophagy Sustains Pancreatic Cancer Growth through Both Cell-Autonomous and Nonautonomous Mechanisms. *Cancer Discovery*, **2018**, 8, 276-287 | 24.4 | 167 |
| 220 | EZH2 inhibition sensitizes BRG1 and EGFR mutant lung tumours to TopoII inhibitors. *Nature*, **2015**, 520, 239-42 | 50.4 | 166 |

| | | | |
|---|---|---|---|
| 219 | Inhibition of ALK, PI3K/MEK, and HSP90 in murine lung adenocarcinoma induced by EML4-ALK fusion oncogene. *Cancer Research*, **2010**, 70, 9827-36 | 10.1 | 164 |
| 218 | Resistance to irreversible EGF receptor tyrosine kinase inhibitors through a multistep mechanism involving the IGF1R pathway. *Cancer Research*, **2013**, 73, 834-43 | 10.1 | 153 |
| 217 | Tumor-propagating cells and Yap/Taz activity contribute to lung tumor progression and metastasis. *EMBO Journal*, **2014**, 33, 468-81 | 13 | 151 |
| 216 | Efficacy of BET bromodomain inhibition in Kras-mutant non-small cell lung cancer. *Clinical Cancer Research*, **2013**, 19, 6183-92 | 12.9 | 150 |
| 215 | Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in EGFR-Mutant Lung Cancer. *Cancer Discovery*, **2015**, 5, 960-971 | 24.4 | 142 |
| 214 | HER2YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy. *Proceedings of the National Academy of Sciences of the United States of America*, **2009**, 106, 474-9 | 11.5 | 141 |
| 213 | Inhibition of KRAS-driven tumorigenicity by interruption of an autocrine cytokine circuit. *Cancer Discovery*, **2014**, 4, 452-65 | 24.4 | 137 |
| 212 | Inhibitor-sensitive FGFR2 and FGFR3 mutations in lung squamous cell carcinoma. *Cancer Research*, **2013**, 73, 5195-205 | 10.1 | 136 |
| 211 | Characterization of Torin2, an ATP-competitive inhibitor of mTOR, ATM, and ATR. *Cancer Research*, **2013**, 73, 2574-86 | 10.1 | 135 |
| 210 | Mutations in BRAF and KRAS converge on activation of the mitogen-activated protein kinase pathway in lung cancer mouse models. *Cancer Research*, **2007**, 67, 4933-9 | 10.1 | 134 |
| 209 | Tumor innate immunity primed by specific interferon-stimulated endogenous retroviruses. *Nature Medicine*, **2018**, 24, 1143-1150 | 50.5 | 131 |
| 208 | Combined use of ALK immunohistochemistry and FISH for optimal detection of ALK-rearranged lung adenocarcinomas. *Journal of Thoracic Oncology*, **2013**, 8, 322-8 | 8.9 | 130 |
| 207 | Hsp90 inhibition suppresses mutant EGFR-T790M signaling and overcomes kinase inhibitor resistance. *Cancer Research*, **2008**, 68, 5827-38 | 10.1 | 129 |
| 206 | Proapoptotic BH3-only BCL-2 family protein BIM connects death signaling from epidermal growth factor receptor inhibition to the mitochondrion. *Cancer Research*, **2007**, 67, 11867-75 | 10.1 | 128 |
| 205 | Mitigation of hematologic radiation toxicity in mice through pharmacological quiescence induced by CDK4/6 inhibition. *Journal of Clinical Investigation*, **2010**, 120, 2528-36 | 15.9 | 127 |
| 204 | PEPCK Coordinates the Regulation of Central Carbon Metabolism to Promote Cancer Cell Growth. *Molecular Cell*, **2015**, 60, 571-83 | 17.6 | 126 |
| 203 | Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition. *Nature Medicine*, **2018**, 24, 968-977 | 50.5 | 126 |
| 202 | LKB1 inhibits lung cancer progression through lysyl oxidase and extracellular matrix remodeling. *Proceedings of the National Academy of Sciences of the United States of America*, **2010**, 107, 18892-7 | 11.5 | 125 |

| | | | |
|---|---|---|---|
| 201 | KDM2B promotes pancreatic cancer via Polycomb-dependent and -independent transcriptional programs. *Journal of Clinical Investigation*, **2013**, 123, 727-39 | 15.9 | 123 |
| 200 | Non-small-cell lung cancer and Ba/F3 transformed cells harboring the ERBB2 G776insV_G/C mutation are sensitive to the dual-specific epidermal growth factor receptor and ERBB2 inhibitor HKI-272. *Cancer Research*, **2006**, 66, 6487-91 | 10.1 | 121 |
| 199 | Primary tumor genotype is an important determinant in identification of lung cancer propagating cells. *Cell Stem Cell*, **2010**, 7, 127-33 | 18 | 120 |
| 198 | Characterization of the cell of origin for small cell lung cancer. *Cell Cycle*, **2011**, 10, 2806-15 | 4.7 | 119 |
| 197 | HIF1 and HIF2 independently activate SRC to promote melanoma metastases. *Journal of Clinical Investigation*, **2013**, 123, 2078-93 | 15.9 | 116 |
| 196 | Ganetespib (STA-9090), a nongeldanamycin HSP90 inhibitor, has potent antitumor activity in in vitro and in vivo models of non-small cell lung cancer. *Clinical Cancer Research*, **2012**, 18, 4973-85 | 12.9 | 115 |
| 195 | HIF2alpha cooperates with RAS to promote lung tumorigenesis in mice. *Journal of Clinical Investigation*, **2009**, 119, 2160-70 | 15.9 | 115 |
| 194 | Intron retention is a source of neoepitopes in cancer. *Nature Biotechnology*, **2018**, 36, 1056-1058 | 44.5 | 114 |
| 193 | Targeting an IKBKE cytokine network impairs triple-negative breast cancer growth. *Journal of Clinical Investigation*, **2014**, 124, 5411-23 | 15.9 | 111 |
| 192 | Single and Dual Targeting of Mutant EGFR with an Allosteric Inhibitor. *Cancer Discovery*, **2019**, 9, 926-943 | 24.4 | 110 |
| 191 | PD-L1 engagement on T cells promotes self-tolerance and suppression of neighboring macrophages and effector T cells in cancer. *Nature Immunology*, **2020**, 21, 442-454 | 19.1 | 110 |
| 190 | Metformin prevents liver tumorigenesis by inhibiting pathways driving hepatic lipogenesis. *Cancer Prevention Research*, **2012**, 5, 544-52 | 3.2 | 109 |
| 189 | Treatment-Induced Tumor Dormancy through YAP-Mediated Transcriptional Reprogramming of the Apoptotic Pathway. *Cancer Cell*, **2020**, 37, 104-122.e12 | 24.3 | 107 |
| 188 | SOX2 and p63 colocalize at genetic loci in squamous cell carcinomas. *Journal of Clinical Investigation* , **2014**, 124, 1636-45 | 15.9 | 105 |
| 187 | Transdifferentiation of lung adenocarcinoma in mice with Lkb1 deficiency to squamous cell carcinoma. *Nature Communications*, **2014**, 5, 3261 | 17.4 | 104 |
| 186 | Suppression of heat shock protein 27 induces long-term dormancy in human breast cancer. *Proceedings of the National Academy of Sciences of the United States of America*, **2012**, 109, 8699-704 | 11.5 | 103 |
| 185 | Interleukin-17A Promotes Lung Tumor Progression through Neutrophil Attraction to Tumor Sites and Mediating Resistance to PD-1 Blockade. *Journal of Thoracic Oncology*, **2017**, 12, 1268-1279 | 8.9 | 99 |
| 184 | Synergistic Immunostimulatory Effects and Therapeutic Benefit of Combined Histone Deacetylase and Bromodomain Inhibition in Non-Small Cell Lung Cancer. *Cancer Discovery*, **2017**, 7, 852-867 | 24.4 | 97 |

| | | | |
|---|---|---|---|
| 183 | Genomic and Functional Fidelity of Small Cell Lung Cancer Patient-Derived Xenografts. *Cancer Discovery*, **2018**, 8, 600-615 | 24.4 | 96 |
| 182 | Interplay between Notch1 and Notch3 promotes EMT and tumor initiation in squamous cell carcinoma. *Nature Communications*, **2017**, 8, 1758 | 17.4 | 95 |
| 181 | LKB1/STK11 inactivation leads to expansion of a prometastatic tumor subpopulation in melanoma. *Cancer Cell*, **2012**, 21, 751-64 | 24.3 | 95 |
| 180 | LKB1 Inactivation Elicits a Redox Imbalance to Modulate Non-small Cell Lung Cancer Plasticity and Therapeutic Response. *Cancer Cell*, **2015**, 27, 698-711 | 24.3 | 94 |
| 179 | Metabolic and functional genomic studies identify deoxythymidylate kinase as a target in LKB1-mutant lung cancer. *Cancer Discovery*, **2013**, 3, 870-9 | 24.4 | 93 |
| 178 | Lysine-specific demethylase 2B (KDM2B)-let-7-enhancer of zester homolog 2 (EZH2) pathway regulates cell cycle progression and senescence in primary cells. *Journal of Biological Chemistry*, **2011**, 286, 33061-9 | 5.4 | 92 |
| 177 | Lkb1 inactivation is sufficient to drive endometrial cancers that are aggressive yet highly responsive to mTOR inhibitor monotherapy. *DMM Disease Models and Mechanisms*, **2010**, 3, 181-93 | 4.1 | 91 |
| 176 | Combined EGFR/MET or EGFR/HSP90 inhibition is effective in the treatment of lung cancers codriven by mutant EGFR containing T790M and MET. *Cancer Research*, **2012**, 72, 3302-11 | 10.1 | 90 |
| 175 | Synergy of radiotherapy and PD-1 blockade in Kras-mutant lung cancer. *JCI Insight*, **2016**, 1, e87415 | 9.9 | 89 |
| 174 | Combined MEK and PI3K inhibition in a mouse model of pancreatic cancer. *Clinical Cancer Research*, **2015**, 21, 396-404 | 12.9 | 88 |
| 173 | Dual targeting of the PI3K/Akt/mTOR pathway as an antitumor strategy in Waldenstrom macroglobulinemia. *Blood*, **2010**, 115, 559-69 | 2.2 | 88 |
| 172 | Clinical implications of monitoring nivolumab immunokinetics in non-small cell lung cancer patients. *JCI Insight*, **2018**, 3, | 9.9 | 86 |
| 171 | The pivotal role of IKK□n the development of spontaneous lung squamous cell carcinomas. *Cancer Cell*, **2013**, 23, 527-40 | 24.3 | 85 |
| 170 | Intratumoral Heterogeneity in EGFR-Mutant NSCLC Results in Divergent Resistance Mechanisms in Response to EGFR Tyrosine Kinase Inhibition. *Cancer Research*, **2015**, 75, 4372-83 | 10.1 | 83 |
| 169 | Profound Tissue Specificity in Proliferation Control Underlies Cancer Drivers and Aneuploidy Patterns. *Cell*, **2018**, 173, 499-514.e23 | 56.2 | 83 |
| 168 | Integrative radiogenomic profiling of squamous cell lung cancer. *Cancer Research*, **2013**, 73, 6289-98 | 10.1 | 83 |
| 167 | Loss of Lkb1 provokes highly invasive endometrial adenocarcinomas. *Cancer Research*, **2008**, 68, 759-66 | 10.1 | 83 |
| 166 | Preexisting oncogenic events impact trastuzumab sensitivity in ERBB2-amplified gastroesophageal adenocarcinoma. *Journal of Clinical Investigation*, **2014**, 124, 5145-58 | 15.9 | 81 |

| | | | |
|---|---|---|---|
| 165 | CDK7 Inhibition Potentiates Genome Instability Triggering Anti-tumor Immunity in Small Cell Lung Cancer. *Cancer Cell*, **2020**, 37, 37-54.e9 | 24.3 | 73 |
| 164 | Allele-dependent variation in the relative cellular potency of distinct EGFR inhibitors. *Cancer Biology and Therapy*, **2007**, 6, 661-7 | 4.6 | 72 |
| 163 | Oncogenic Deregulation of EZH2 as an Opportunity for Targeted Therapy in Lung Cancer. *Cancer Discovery*, **2016**, 6, 1006-21 | 24.4 | 71 |
| 162 | Alu elements mediate MYB gene tandem duplication in human T-ALL. *Journal of Experimental Medicine*, **2007**, 204, 3059-66 | 16.6 | 71 |
| 161 | EZH2-Mediated Primary Cilium Deconstruction Drives Metastatic Melanoma Formation. *Cancer Cell*, **2018**, 34, 69-84.e14 | 24.3 | 71 |
| 160 | Development of Selective Covalent Janus Kinase 3 Inhibitors. *Journal of Medicinal Chemistry*, **2015**, 58, 6589-606 | 8.3 | 70 |
| 159 | Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity. *Cancer Cell*, **2019**, 36, 444-457.e7 | 24.3 | 69 |
| 158 | A dual role for the immune response in a mouse model of inflammation-associated lung cancer. *Journal of Clinical Investigation*, **2011**, 121, 2436-46 | 15.9 | 68 |
| 157 | Epigenetic CRISPR Screen Identifies as an Immunotherapeutic Target in -Mutant Lung Adenocarcinoma. *Cancer Discovery*, **2020**, 10, 270-287 | 24.4 | 68 |
| 156 | Suppression of Adaptive Responses to Targeted Cancer Therapy by Transcriptional Repression. *Cancer Discovery*, **2018**, 8, 59-73 | 24.4 | 67 |
| 155 | Regression of drug-resistant lung cancer by the combination of rosiglitazone and carboplatin. *Clinical Cancer Research*, **2008**, 14, 6478-86 | 12.9 | 67 |
| 154 | Clinical Characteristics and Outcomes of COVID-19-Infected Cancer Patients: A Systematic Review and Meta-Analysis. *Journal of the National Cancer Institute*, **2021**, 113, 371-380 | 9.7 | 66 |
| 153 | New cast for a new era: preclinical cancer drug development revisited. *Journal of Clinical Investigation*, **2013**, 123, 3639-45 | 15.9 | 63 |
| 152 | Small-molecule targeting of brachyury transcription factor addiction in chordoma. *Nature Medicine*, **2019**, 25, 292-300 | 50.5 | 62 |
| 151 | Cetuximab response of lung cancer-derived EGF receptor mutants is associated with asymmetric dimerization. *Cancer Research*, **2013**, 73, 6770-9 | 10.1 | 61 |
| 150 | Ecatenin contributes to lung tumor development induced by EGFR mutations. *Cancer Research*, **2014**, 74, 5891-902 | 10.1 | 60 |
| 149 | DNA-dependent protein kinase catalytic subunit is not required for dysfunctional telomere fusion and checkpoint response in the telomerase-deficient mouse. *Molecular and Cellular Biology*, **2007**, 27, 2253-65 | 4.8 | 60 |
| 148 | Inhibition of MUC1-C Suppresses MYC Expression and Attenuates Malignant Growth in KRAS Mutant Lung Adenocarcinomas. *Cancer Research*, **2016**, 76, 1538-48 | 10.1 | 59 |

| | | | |
|---|---|---|---|
| 147 | Failure to induce apoptosis via BCL-2 family proteins underlies lack of efficacy of combined MEK and PI3K inhibitors for KRAS-mutant lung cancers. *Cancer Research*, **2014**, 74, 3146-56 | 10.1 | 57 |
| 146 | Activating Mutations in ERBB2 and Their Impact on Diagnostics and Treatment. *Frontiers in Oncology*, **2013**, 3, 86 | 5.3 | 57 |
| 145 | Activation of FOXO3a is sufficient to reverse mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor chemoresistance in human cancer. *Cancer Research*, **2010**, 70, 4709-18 | 10.1 | 57 |
| 144 | Autophagy Inhibition Dysregulates TBK1 Signaling and Promotes Pancreatic Inflammation. *Cancer Immunology Research*, **2016**, 4, 520-30 | 12.5 | 57 |
| 143 | Neurotrophin receptor TrkB promotes lung adenocarcinoma metastasis. *Proceedings of the National Academy of Sciences of the United States of America*, **2014**, 111, 10299-304 | 11.5 | 56 |
| 142 | Respiratory failure due to differentiation arrest and expansion of alveolar cells following lung-specific loss of the transcription factor C/EBPalpha in mice. *Molecular and Cellular Biology*, **2006**, 26, 1109-23 | 4.8 | 56 |
| 141 | Activation of Oxidative Stress Response in Cancer Generates a Druggable Dependency on Exogenous Non-essential Amino Acids. *Cell Metabolism*, **2020**, 31, 339-350.e4 | 24.6 | 56 |
| 140 | ER Stress Signaling Promotes the Survival of Cancer "Persister Cells" Tolerant to EGFR Tyrosine Kinase Inhibitors. *Cancer Research*, **2018**, 78, 1044-1057 | 10.1 | 55 |
| 139 | BORIS promotes chromatin regulatory interactions in treatment-resistant cancer cells. *Nature*, **2019**, 572, 676-680 | 50.4 | 55 |
| 138 | Cytotoxic T Cells in PD-L1-Positive Malignant Pleural Mesotheliomas Are Counterbalanced by Distinct Immunosuppressive Factors. *Cancer Immunology Research*, **2016**, 4, 1038-1048 | 12.5 | 54 |
| 137 | D-2-hydroxyglutarate produced by mutant IDH2 causes cardiomyopathy and neurodegeneration in mice. *Genes and Development*, **2014**, 28, 479-90 | 12.6 | 54 |
| 136 | Targeting Aberrations in Non-Small Cell Lung Cancer with Osimertinib. *Clinical Cancer Research*, **2018**, 24, 2594-2604 | 12.9 | 53 |
| 135 | BET Bromodomain Inhibition Cooperates with PD-1 Blockade to Facilitate Antitumor Response in -Mutant Non-Small Cell Lung Cancer. *Cancer Immunology Research*, **2018**, 6, 1234-1245 | 12.5 | 53 |
| 134 | The Combined Effect of FGFR Inhibition and PD-1 Blockade Promotes Tumor-Intrinsic Induction of Antitumor Immunity. *Cancer Immunology Research*, **2019**, 7, 1457-1471 | 12.5 | 53 |
| 133 | Long-term Benefit of PD-L1 Blockade in Lung Cancer Associated with JAK3 Activation. *Cancer Immunology Research*, **2015**, 3, 855-63 | 12.5 | 53 |
| 132 | SHP2 inhibition diminishes KRASG12C cycling and promotes tumor microenvironment remodeling. *Journal of Experimental Medicine*, **2021**, 218, | 16.6 | 53 |
| 131 | Suppression of Myeloid Cell Arginase Activity leads to Therapeutic Response in a NSCLC Mouse Model by Activating Anti-Tumor Immunity **2019**, 7, 32 | | 50 |
| 130 | Outcomes by tumor histology and KRAS mutation status after lung stereotactic body radiation therapy for early-stage non-small-cell lung cancer. *Clinical Lung Cancer*, **2015**, 16, 24-32 | 4.9 | 50 |

| | | | |
|---|---|---|---|
| 129 | Co-clinical trials demonstrate superiority of crizotinib to chemotherapy in ALK-rearranged non-small cell lung cancer and predict strategies to overcome resistance. *Clinical Cancer Research*, **2014**, 20, 1204-1211 | 12.9 | 49 |
| 128 | MUC1-C confers EMT and KRAS independence in mutant KRAS lung cancer cells. *Oncotarget*, **2014**, 5, 8893-905 | 3.3 | 48 |
| 127 | Lkb1 inactivation drives lung cancer lineage switching governed by Polycomb Repressive Complex 2. *Nature Communications*, **2017**, 8, 14922 | 17.4 | 47 |
| 126 | Alterations of LKB1 and KRAS and risk of brain metastasis: comprehensive characterization by mutation analysis, copy number, and gene expression in non-small-cell lung carcinoma. *Lung Cancer*, **2014**, 86, 255-61 | 5.9 | 47 |
| 125 | LKB1 loss promotes endometrial cancer progression via CCL2-dependent macrophage recruitment. *Journal of Clinical Investigation*, **2015**, 125, 4063-76 | 15.9 | 47 |
| 124 | JAK2/IDH-mutant-driven myeloproliferative neoplasm is sensitive to combined targeted inhibition. *Journal of Clinical Investigation*, **2018**, 128, 789-804 | 15.9 | 47 |
| 123 | In vivo CRISPR screening unveils histone demethylase UTX as an important epigenetic regulator in lung tumorigenesis. *Proceedings of the National Academy of Sciences of the United States of America*, **2018**, 115, E3978-E3986 | 11.5 | 45 |
| 122 | Targeting the oncogenic MUC1-C protein inhibits mutant EGFR-mediated signaling and survival in non-small cell lung cancer cells. *Clinical Cancer Research*, **2014**, 20, 5423-34 | 12.9 | 45 |
| 121 | Cigarette smoking increases copy number alterations in nonsmall-cell lung cancer. *Proceedings of the National Academy of Sciences of the United States of America*, **2011**, 108, 16345-50 | 11.5 | 45 |
| 120 | Inflammatory cytokines in major depressive disorder: A case-control study. *Australian and New Zealand Journal of Psychiatry*, **2017**, 51, 23-31 | 2.6 | 43 |
| 119 | Identification of Wee1 as a novel therapeutic target for mutant RAS-driven acute leukemia and other malignancies. *Leukemia*, **2015**, 29, 27-37 | 10.7 | 43 |
| 118 | CDK4/6 or MAPK blockade enhances efficacy of EGFR inhibition in oesophageal squamous cell carcinoma. *Nature Communications*, **2017**, 8, 13897 | 17.4 | 42 |
| 117 | Targeting glutamine-addiction and overcoming CDK4/6 inhibitor resistance in human esophageal squamous cell carcinoma. *Nature Communications*, **2019**, 10, 1296 | 17.4 | 42 |
| 116 | New Approaches to SCLC Therapy: From the Laboratory to the Clinic. *Journal of Thoracic Oncology*, **2020**, 15, 520-540 | 8.9 | 42 |
| 115 | Overcoming Resistance to the THZ Series of Covalent Transcriptional CDK Inhibitors. *Cell Chemical Biology*, **2018**, 25, 135-142.e5 | 8.2 | 42 |
| 114 | Acquired resistance to dasatinib in lung cancer cell lines conferred by DDR2 gatekeeper mutation and NF1 loss. *Molecular Cancer Therapeutics*, **2014**, 13, 475-82 | 6.1 | 42 |
| 113 | TFE3 contains two activation domains, one acidic and the other proline-rich, that synergistically activate transcription. *Nucleic Acids Research*, **1995**, 23, 3865-71 | 20.1 | 42 |
| 112 | MUC1-C regulates lineage plasticity driving progression to neuroendocrine prostate cancer. *Nature Communications*, **2020**, 11, 338 | 17.4 | 41 |

| | | | |
|---|---|---|---|
| 111 | HKI-272 in non small cell lung cancer. *Clinical Cancer Research*, **2007**, 13, s4593-6 | 12.9 | 41 |
| 110 | Gain-of-Function Mutations Promote Focal Adhesion Kinase Activation and Dependency in Diffuse Gastric Cancer. *Cancer Discovery*, **2020**, 10, 288-305 | 24.4 | 41 |
| 109 | Telomere dysfunction promotes genome instability and metastatic potential in a K-ras p53 mouse model of lung cancer. *Carcinogenesis*, **2008**, 29, 747-53 | 4.6 | 40 |
| 108 | Therapeutic anti-EGFR antibody 806 generates responses in murine de novo EGFR mutant-dependent lung carcinomas. *Journal of Clinical Investigation*, **2007**, 117, 346-52 | 15.9 | 40 |
| 107 | Telomere length and telomerase in a well-characterized sample of individuals with major depressive disorder compared to controls. *Psychoneuroendocrinology*, **2015**, 58, 9-22 | 5 | 39 |
| 106 | RMRP is a non-coding RNA essential for early murine development. *PLoS ONE*, **2011**, 6, e26270 | 3.7 | 39 |
| 105 | The CRTC1-NEDD9 signaling axis mediates lung cancer progression caused by LKB1 loss. *Cancer Research*, **2012**, 72, 6502-11 | 10.1 | 39 |
| 104 | Defining an inflamed tumor immunophenotype in recurrent, metastatic squamous cell carcinoma of the head and neck. *Oral Oncology*, **2017**, 67, 61-69 | 4.4 | 35 |
| 103 | Image-guided radiotherapy platform using single nodule conditional lung cancer mouse models. *Nature Communications*, **2014**, 5, 5870 | 17.4 | 35 |
| 102 | Mouse models of lung cancer. *Clinical Cancer Research*, **2006**, 12, 4396s-4402s | 12.9 | 35 |
| 101 | Lower Airway Dysbiosis Affects Lung Cancer Progression. *Cancer Discovery*, **2021**, 11, 293-307 | 24.4 | 34 |
| 100 | Mobocertinib (TAK-788): A Targeted Inhibitor of Exon 20 Insertion Mutants in Non-Small Cell Lung Cancer. *Cancer Discovery*, **2021**, 11, 1672-1687 | 24.4 | 34 |
| 99 | High MITF Expression Is Associated with Super-Enhancers and Suppressed by CDK7 Inhibition in Melanoma. *Journal of Investigative Dermatology*, **2018**, 138, 1582-1590 | 4.3 | 33 |
| 98 | Targeting PKC as a Therapeutic Strategy against Heterogeneous Mechanisms of EGFR Inhibitor Resistance in EGFR-Mutant Lung Cancer. *Cancer Cell*, **2018**, 34, 954-969.e4 | 24.3 | 33 |
| 97 | Noncanonical agonist PPAR ligands modulate the response to DNA damage and sensitize cancer cells to cytotoxic chemotherapy. *Proceedings of the National Academy of Sciences of the United States of America*, **2018**, 115, 561-566 | 11.5 | 32 |
| 96 | Branched-Chain Amino Acid Metabolic Reprogramming Orchestrates Drug Resistance to EGFR Tyrosine Kinase Inhibitors. *Cell Reports*, **2019**, 28, 512-525.e6 | 10.6 | 32 |
| 95 | Evaluating TBK1 as a therapeutic target in cancers with activated IRF3. *Molecular Cancer Research*, **2014**, 12, 1055-66 | 6.6 | 32 |
| 94 | Cullin5 deficiency promotes small-cell lung cancer metastasis by stabilizing integrin 1. *Journal of Clinical Investigation*, **2019**, 129, 972-987 | 15.9 | 32 |

| | | | |
|---|---|---|---|
| 93 | Sunitinib prolongs survival in genetically engineered mouse models of multistep lung carcinogenesis. *Cancer Prevention Research*, **2009**, 2, 330-7 | 3.2 | 31 |
| 92 | Identification and characterization of an alternative cancer-derived PD-L1 splice variant. *Cancer Immunology, Immunotherapy*, **2019**, 68, 407-420 | 7.4 | 31 |
| 91 | The KDM5A/RBP2 histone demethylase represses NOTCH signaling to sustain neuroendocrine differentiation and promote small cell lung cancer tumorigenesis. *Genes and Development*, **2019**, 33, 1718-1738 | 12.6 | 29 |
| 90 | MUC1-C activates EZH2 expression and function in human cancer cells. *Scientific Reports*, **2017**, 7, 7481 | 4.9 | 29 |
| 89 | Kinase domain activation of FGFR2 yields high-grade lung adenocarcinoma sensitive to a Pan-FGFR inhibitor in a mouse model of NSCLC. *Cancer Research*, **2014**, 74, 4676-84 | 10.1 | 29 |
| 88 | Temporal molecular and biological assessment of an erlotinib-resistant lung adenocarcinoma model reveals markers of tumor progression and treatment response. *Cancer Research*, **2012**, 72, 5921-33 | 10.1 | 29 |
| 87 | NSCLC Driven by DDR2 Mutation Is Sensitive to Dasatinib and JQ1 Combination Therapy. *Molecular Cancer Therapeutics*, **2015**, 14, 2382-2389 | 6.1 | 28 |
| 86 | MUC1-C promotes the suppressive immune microenvironment in non-small cell lung cancer. *OncoImmunology*, **2017**, 6, e1338998 | 7.2 | 28 |
| 85 | EGFR targeted therapy: view from biological standpoint. *Cell Cycle*, **2006**, 5, 2072-6 | 4.7 | 27 |
| 84 | Palbociclib resistance confers dependence on an FGFR-MAP kinase-mTOR-driven pathway in -mutant non-small cell lung cancer. *Oncotarget*, **2018**, 9, 31572-31589 | 3.3 | 27 |
| 83 | Prospective association between major depressive disorder and leukocyte telomere length over two years. *Psychoneuroendocrinology*, **2018**, 90, 157-164 | 5 | 26 |
| 82 | Assessing Therapeutic Efficacy of MEK Inhibition in a KRAS-Driven Mouse Model of Lung Cancer. *Clinical Cancer Research*, **2018**, 24, 4854-4864 | 12.9 | 26 |
| 81 | Identification of Oncogenic and Drug-Sensitizing Mutations in the Extracellular Domain of FGFR2. *Cancer Research*, **2015**, 75, 3139-46 | 10.1 | 26 |
| 80 | Targeting the human MUC1-C oncoprotein with an antibody-drug conjugate. *JCI Insight*, **2018**, 3, | 9.9 | 26 |
| 79 | Pulsatile MEK Inhibition Improves Anti-tumor Immunity and T Cell Function in Murine Kras Mutant Lung Cancer. *Cell Reports*, **2019**, 27, 806-819.e5 | 10.6 | 25 |
| 78 | Comparative transcriptomes of adenocarcinomas and squamous cell carcinomas reveal molecular similarities that span classical anatomic boundaries. *PLoS Genetics*, **2017**, 13, e1006938 | 6 | 25 |
| 77 | Overexpression of wildtype EGFR is tumorigenic and denotes a therapeutic target in non-small cell lung cancer. *Oncotarget*, **2016**, 7, 3884-96 | 3.3 | 25 |
| 76 | De novo lipogenesis represents a therapeutic target in mutant Kras non-small cell lung cancer. *FASEB Journal*, **2018**, 32, fj201800204 | 0.9 | 24 |

| | | | |
|---|---|---|---|
| 75 | The KRAS Inhibitor MRTX849 Reconditions the Tumor Immune Microenvironment and Sensitizes Tumors to Checkpoint Inhibitor Therapy. *Molecular Cancer Therapeutics*, **2021**, 20, 975-985 | 6.1 | 24 |
| 74 | Overcoming Resistance to Dual Innate Immune and MEK Inhibition Downstream of KRAS. *Cancer Cell*, **2018**, 34, 439-452.e6 | 24.3 | 24 |
| 73 | CXCR7 Reactivates ERK Signaling to Promote Resistance to EGFR Kinase Inhibitors in NSCLC. *Cancer Research*, **2019**, 79, 4439-4452 | 10.1 | 23 |
| 72 | Integrative genomic analysis reveals a high frequency of LKB1 genetic alteration in Chinese lung adenocarcinomas. *Journal of Thoracic Oncology*, **2014**, 9, 254-8 | 8.9 | 22 |
| 71 | A common p53 mutation (R175H) activates c-Met receptor tyrosine kinase to enhance tumor cell invasion. *Cancer Biology and Therapy*, **2013**, 14, 853-9 | 4.6 | 22 |
| 70 | The age of cancer: telomeres, checkpoints, and longevity. *Journal of Clinical Investigation*, **2003**, 111, S9-14 | 15.9 | 22 |
| 69 | Generation of Genetically Engineered Mouse Lung Organoid Models for Squamous Cell Lung Cancers Allows for the Study of Combinatorial Immunotherapy. *Clinical Cancer Research*, **2020**, 26, 3431-3442 | 12.9 | 21 |
| 68 | Design and generation of MLPA probe sets for combined copy number and small-mutation analysis of human genes: EGFR as an example. *Scientific World Journal, The*, **2010**, 10, 2003-18 | 2.2 | 21 |
| 67 | Differential roles of telomere attrition in type I and II endometrial carcinogenesis. *American Journal of Pathology*, **2008**, 173, 536-44 | 5.8 | 21 |
| 66 | Abstract B290: Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. **2013**, | | 21 |
| 65 | CD54-NOTCH1 axis controls tumor initiation and cancer stem cell functions in human prostate cancer. *Theranostics*, **2017**, 7, 67-80 | 12.1 | 20 |
| 64 | Loss of p53 attenuates the contribution of IL-6 deletion on suppressed tumor progression and extended survival in Kras-driven murine lung cancer. *PLoS ONE*, **2013**, 8, e80885 | 3.7 | 20 |
| 63 | NK Cells Mediate Synergistic Antitumor Effects of Combined Inhibition of HDAC6 and BET in a SCLC Preclinical Model. *Cancer Research*, **2018**, 78, 3709-3717 | 10.1 | 20 |
| 62 | FBXO4 loss facilitates carcinogen induced papilloma development in mice. *Cancer Biology and Therapy*, **2015**, 16, 750-5 | 4.6 | 19 |
| 61 | Rapamycin prevents the development and progression of mutant epidermal growth factor receptor lung tumors with the acquired resistance mutation T790M. *Cell Reports*, **2014**, 7, 1824-32 | 10.6 | 19 |
| 60 | NF-kappaB fans the flames of lung carcinogenesis. *Cancer Prevention Research*, **2010**, 3, 403-5 | 3.2 | 19 |
| 59 | Characterization of the Immune Landscape of EGFR-Mutant NSCLC Identifies CD73/Adenosine Pathway as a Potential Therapeutic Target. *Journal of Thoracic Oncology*, **2021**, 16, 583-600 | 8.9 | 18 |
| 58 | ULK1 inhibition overcomes compromised antigen presentation and restores antitumor immunity in LKB1 mutant lung cancer. *Nature Cancer*, **2021**, 2, 503-514 | 15.4 | 18 |

| | | | |
|---|---|---|---|
| 57 | Synergy of WEE1 and mTOR Inhibition in Mutant -Driven Lung Cancers. *Clinical Cancer Research*, **2017**, 23, 6993-7005 | 12.9 | 17 |
| 56 | Molecular determinants of response to matuzumab in combination with paclitaxel for patients with advanced non-small cell lung cancer. *Molecular Cancer Therapeutics*, **2009**, 8, 481-9 | 6.1 | 17 |
| 55 | Ewing sarcoma mimicking atypical carcinoid tumor: detection of unexpected genomic alterations demonstrates the use of next generation sequencing as a diagnostic tool. *Cancer Genetics*, **2014**, 207, 335-9 | 2.3 | 16 |
| 54 | Gemcitabine and Chk1 Inhibitor AZD7762 Synergistically Suppress the Growth of Lkb1-Deficient Lung Adenocarcinoma. *Cancer Research*, **2017**, 77, 5068-5076 | 10.1 | 16 |
| 53 | Searching for a magic bullet in NSCLC: the role of epidermal growth factor receptor mutations and tyrosine kinase inhibitors. *Lung Cancer*, **2008**, 60 Suppl 2, S10-8 | 5.9 | 16 |
| 52 | A systems biology pipeline identifies regulatory networks for stem cell engineering. *Nature Biotechnology*, **2019**, 37, 810-818 | 44.5 | 14 |
| 51 | The LKB1 tumor suppressor as a biomarker in mouse and human tissues. *PLoS ONE*, **2013**, 8, e73449 | 3.7 | 14 |
| 50 | Innate T Cells Mediate Antitumor Immunity by Orchestrating Immunogenic Macrophage Programming. *Cancer Discovery*, **2019**, 9, 1288-1305 | 24.4 | 13 |
| 49 | Epidermal growth factor receptor as a novel molecular target for aggressive papillary tumors in the middle ear and temporal bone. *Oncotarget*, **2015**, 6, 11357-68 | 3.3 | 13 |
| 48 | BRG1 Loss Predisposes Lung Cancers to Replicative Stress and ATR Dependency. *Cancer Research*, **2020**, 80, 3841-3854 | 10.1 | 13 |
| 47 | Multiple screening approaches reveal HDAC6 as a novel regulator of glycolytic metabolism in triple-negative breast cancer. *Science Advances*, **2021**, 7, | 14.3 | 13 |
| 46 | Use of Patient-Derived Tumor Organotypic Spheroids to Identify Combination Therapies for Mutant Non-Small Cell Lung Cancer. *Clinical Cancer Research*, **2020**, 26, 2393-2403 | 12.9 | 12 |
| 45 | Upregulation of IGF1R by mutant RAS in leukemia and potentiation of RAS signaling inhibitors by small-molecule inhibition of IGF1R. *Clinical Cancer Research*, **2014**, 20, 5483-95 | 12.9 | 12 |
| 44 | Walking the telomere plank into cancer. *Journal of the National Cancer Institute*, **2003**, 95, 1184-6 | 9.7 | 12 |
| 43 | Notch inhibition overcomes resistance to tyrosine kinase inhibitors in EGFR-driven lung adenocarcinoma. *Journal of Clinical Investigation*, **2020**, 130, 612-624 | 15.9 | 12 |
| 42 | STOP gene Phactr4 is a tumor suppressor. *Proceedings of the National Academy of Sciences of the United States of America*, **2013**, 110, E407-14 | 11.5 | 11 |
| 41 | Co-clinical quantitative tumor volume imaging in ALK-rearranged NSCLC treated with crizotinib. *European Journal of Radiology*, **2017**, 88, 15-20 | 4.7 | 10 |
| 40 | Abstract 1: Oncogenic extracellular domain mutations of ERBB2 in cancer **2012**, | | 9 |

| | | | |
|---|---|---|---|
| 39 | An Empirical Antigen Selection Method Identifies Neoantigens That Either Elicit Broad Antitumor T-cell Responses or Drive Tumor Growth. *Cancer Discovery*, **2021**, 11, 696-713 | 24.4 | 9 |
| 38 | Epigenetic CRISPR Screens Identify as a Therapeutic Vulnerability in Non-Small Cell Lung Cancer. *Cancer Research*, **2020**, 80, 3556-3567 | 10.1 | 8 |
| 37 | Serial single-cell profiling analysis of metastatic TNBC during Nab-paclitaxel and pembrolizumab treatment. *Breast Cancer Research and Treatment*, **2021**, 185, 85-94 | 4.4 | 8 |
| 36 | EZH2 Inhibitors: Take It EZy, It Is All About Context. *Cancer Discovery*, **2019**, 9, 472-475 | 24.4 | 7 |
| 35 | C7-04: Efficacy of BIBW 2992, a potent irreversible inhibitor of EGFR and HER2 in human NSCLC xenografts and in a transgenic mouse lung-cancer model. *Journal of Thoracic Oncology*, **2007**, 2, S380 | 8.9 | 7 |
| 34 | Phenformin enhances the therapeutic effect of selumetinib in KRAS-mutant non-small cell lung cancer irrespective of LKB1 status. *Oncotarget*, **2017**, 8, 59008-59022 | 3.3 | 7 |
| 33 | Magnetic resonance imaging of the response of a mouse model of non-small cell lung cancer to tyrosine kinase inhibitor treatment. *Comparative Medicine*, **2008**, 58, 276-81 | 1.6 | 7 |
| 32 | The impact of the MYB-NFIB fusion proto-oncogene in vivo. *Oncotarget*, **2016**, 7, 31681-8 | 3.3 | 7 |
| 31 | Functional genomics reveals that tumors with activating phosphoinositide 3-kinase mutations are dependent on accelerated protein turnover. *Genes and Development*, **2016**, 30, 2684-2695 | 12.6 | 7 |
| 30 | Targeting Exon 20 Insertion-Mutant Lung Adenocarcinoma with a Novel Tyrosine Kinase Inhibitor Mobocertinib. *Cancer Research*, **2021**, 81, 5311-5324 | 10.1 | 7 |
| 29 | Cell Division Cycle 42 plays a Cell type-Specific role in Lung Tumorigenesis. *Scientific Reports*, **2017**, 7, 10407 | 4.9 | 6 |
| 28 | Reprogramming of the esophageal squamous carcinoma epigenome by SOX2 promotes ADAR1 dependence. *Nature Genetics*, **2021**, 53, 881-894 | 36.3 | 6 |
| 27 | MUC1-C integrates activation of the IFN- pathway with suppression of the tumor immune microenvironment in triple-negative breast cancer **2021**, 9, | | 6 |
| 26 | Combined Inhibition of SHP2 and CXCR1/2 Promotes Anti-Tumor T Cell Response in NSCLC. *Cancer Discovery*, **2021**, | 24.4 | 6 |
| 25 | Acquired substrate preference for GAB1 protein bestows transforming activity to ERBB2 kinase lung cancer mutants. *Journal of Biological Chemistry*, **2013**, 288, 16895-16904 | 5.4 | 5 |
| 24 | Temporal dissection of K-ras(G12D) mutant in vitro and in vivo using a regulatable K-ras(G12D) mouse allele. *PLoS ONE*, **2012**, 7, e37308 | 3.7 | 5 |
| 23 | Cellular Origins of EGFR-Driven Lung Cancer Cells Determine Sensitivity to Therapy. *Advanced Science*, **2021**, 8, e2101999 | 13.6 | 5 |
| 22 | Loss of Smad4 promotes aggressive lung cancer metastasis by de-repression of PAK3 via miRNA regulation. *Nature Communications*, **2021**, 12, 4853 | 17.4 | 5 |

| | | | |
|---|---|---|---|
| 21 | Shining a light on metabolic vulnerabilities in non-small cell lung cancer. *Biochimica Et Biophysica Acta: Reviews on Cancer*, **2021**, 1875, 188462 | 11.2 | 4 |
| 20 | Ontogeny and Vulnerabilities of Drug-Tolerant Persisters in HER2+ Breast Cancer.. *Cancer Discovery* , **2021**, | 24.4 | 4 |
| 19 | Abstract LB-410: Phase I dose escalation study of MM-121, a fully human monoclonal antibody to ErbB3, in patients with advanced solid tumors **2011**, | | 3 |
| 18 | A novel in vivo model for studying conditional dual loss of BLIMP-1 and p53 in B-cells, leading to tumor transformation. *American Journal of Hematology*, **2017**, 92, E138-E145 | 7.1 | 2 |
| 17 | Targeting Transcriptional Addictions in Small Cell Lung Cancer with a Covalent CDK7 Inhibitor. *Cancer Cell*, **2015**, 27, 149 | 24.3 | 2 |
| 16 | MUC1-C integrates type II interferon and chromatin remodeling pathways in immunosuppression of prostate cancer.. *OncoImmunology*, **2022**, 11, 2029298 | 7.2 | 2 |
| 15 | Loss of sensitizes immune checkpoint blockade in non-small cell lung cancer.. *Science Advances*, **2022**, 8, eabi9533 | 14.3 | 2 |
| 14 | CCAAT/enhancer binding protein is dispensable for development of lung adenocarcinoma. *PLoS ONE*, **2015**, 10, e0120647 | 3.7 | 2 |
| 13 | Recent advances in preclinical models for lung squamous cell carcinoma. *Oncogene*, **2021**, 40, 2817-2829 | 9.2 | 2 |
| 12 | Pan-ERBB kinase inhibition augments CDK4/6 inhibitor efficacy in oesophageal squamous cell carcinoma. *Gut*, **2021**, | 19.2 | 2 |
| 11 | Ground-glass opacity-featured lung adenocarcinoma has no response to chemotherapy. *Journal of Cancer Research and Clinical Oncology*, **2020**, 146, 2411-2417 | 4.9 | 1 |
| 10 | Can mouse models of cancer reliably improve clinical trial outcome?. *Clinical Investigation*, **2013**, 3, 119-130 | | 1 |
| 9 | Ontogeny and Vulnerabilities of Drug-Tolerant Persisters in HER2+ Breast Cancer | | 1 |
| 8 | Targeting the Atf7ip-Setdb1 Complex Augments Antitumor Immunity by Boosting Tumor Immunogenicity. *Cancer Immunology Research*, **2021**, 9, 1298-1315 | 12.5 | 1 |
| 7 | Targeting HSPA1A in ARID2-deficient lung adenocarcinoma. *National Science Review*, **2021**, 8, nwab014 | 10.8 | 1 |
| 6 | A novel EGFR inhibitor suppresses survivin expression and tumor growth in human gefitinib-resistant EGFR-wild type and -T790M non-small cell lung cancer. *Biochemical Pharmacology* , **2021**, 193, 114792 | 6 | 0 |
| 5 | Using stem cell biology to design precision medicine for non-small cell lung cancer. *Journal of Thoracic Oncology*, **2016**, 11, S4-S5 | 8.9 | |
| 4 | Large Scale Copy Number Variation Upregulates the Expression of MYB in Human T-ALL.. *Blood*, **2006**, 108, 1408-1408 | 2.2 | |

| | | |
|---|---|---|
| 3 | Phenformin combines with selumetinib in targeting KRAS mutant non-small cell lung cancer cells with alternative LKB1 status.. *Journal of Clinical Oncology*, **2014**, 32, 2589-2589 | 2.2 |
| 2 | Mouse models of cancer how to optimize their predictive value in cancer drug development. *FASEB Journal*, **2013**, 27, 1088.17 | 0.9 |
| 1 | Response to Cottu, Bozec, Basse, and Paoletti. *Journal of the National Cancer Institute*, **2021**, 113, 344-345 | 57 |